Home Single Peptide Dosages 5-Amino-1MQ (10 mg Vial) Dosage Protocol

5-Amino-1MQ (10 mg Vial) Dosage Protocol

5-Amino-1MQ (10 mg Vial) Dosage Protocol

5-Aminio-1MQ-10mg research peptide vial with dosage and benefit information

Quickstart Highlights

5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels[1][2]. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency[3]. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration.
  • Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks[4].

Dosing & Reconstitution Guide

Subcutaneous, once or twice daily

Subcutaneous Protocol (2 mL = 5 mg/mL)

Phase Daily Dose (mg) Units (per injection) (mL)
Days 1–2 (Tolerance) 2.5 mg (2500 mcg) 50 units (0.50 mL)
Days 3+ (Standard) 5 mg (5000 mcg) 100 units (1.00 mL)
Alternative BID 2.5 mg twice daily 50 units (0.50 mL) × 2

Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours[5], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 10 mg vial provides 2–4 days of material at these doses.

Reconstitution Steps

  1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
  2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
  5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
Important: This guide is for educational purposes only and is not medical advice.

Supplies Needed

Plan based on protocol duration using the 10 mg vial format at 5 mg/day.

  • 5-Amino-1MQ Vials (10 mg each):
    • 1 week (5 mg/day = 35 mg total) → 4 vials
    • 2 weeks (5 mg/day = 70 mg total) → 7 vials
    • 4 weeks (5 mg/day = 140 mg total) → 14 vials
  • Insulin Syringes (U-100, 1 mL):
    • 1 week (once daily): 7 syringes
    • 2 weeks (once daily): 14 syringes
    • 4 weeks (once daily): 28 syringes
  • Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
    • 1 week (4 vials × 2.0 mL = 8 mL) → 1 × 10 mL bottle
    • 2 weeks (7 vials × 2.0 mL = 14 mL) → 2 × 10 mL bottles
    • 4 weeks (14 vials × 2.0 mL = 28 mL) → 3 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
    • 1 week (once daily): 14 swabs
    • 2 weeks (once daily): 28 swabs
    • 4 weeks (once daily): 56 swabs → recommend 1 × 100-count box
5-Aminio-1MQ-10mg research peptide vial with dosage and benefit information View Supplier
Insulin Syringes for subcutaneous peptide injection View Supplier
Bacteriostatic water 10ml for peptide reconstitution View Supplier
EasyTouch alcohol prep pads for injection site sterilization View Supplier

Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels[1][2].
  • Schedule: Daily subcutaneous injections; each 10 mg vial provides 2–4 days of material.
  • Dose Range: 2.5–5 mg once or twice daily.
  • Reconstitution: 2.0 mL per 10 mg vial (5 mg/mL) for accurate measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

Dosing Protocol

Suggested approach for the 10 mg vial format.

  • Start: 2.5 mg once daily to assess tolerance.
  • Target: 5 mg once daily or 2.5 mg twice daily (BID).
  • Frequency: Once or twice per day (subcutaneous).
  • Vial Duration: Single 10 mg vial lasts 2–4 days at standard doses.
  • Timing: Morning administration preferred; BID dosing may be split AM/PM.

Storage Instructions

Proper storage preserves compound stability.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
  • Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
  • Do not refreeze reconstituted solution.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each administration; dispose in a sharps container[6].
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[7].
  • Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
  • Document daily dose and site rotation to maintain consistency.
  • The 10 mg vial format requires multiple vials for extended protocols; plan supplies accordingly.

How This Works

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT)[1]. NNMT is a cytosolic enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability[2].

By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis via the salvage pathway, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis, fat oxidation, and metabolic flexibility[3]. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake[8][9].

Potential Benefits & Side Effects

Observations from preclinical and early research literature.

  • May support reductions in fat mass while preserving lean muscle in animal models[8][9].
  • Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3].
  • Enhanced grip strength observed in aged mice when combined with exercise[10].
  • Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions.
  • Long-term human safety data not established; this compound remains investigational.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity—preclinical data suggest synergy with exercise[10].
  • Prioritize sleep and stress management to support metabolic adaptation.
  • Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols[11].

Injection Technique

General subcutaneous guidance from clinical best-practice resources[6].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[7].
  • Slow injection may minimize any stinging sensation associated with the compound.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • Nature Medicine (2014)
    — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
    View Source

  • PMC (2024)
    — Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions
    View Source

  • Frontiers in Pharmacology (2024)
    — NNMT: a novel therapeutic target for metabolic syndrome
    View Source

  • Creative Peptides
    — Peptide stability and storage guidelines for lyophilized compounds
    View Source

  • PubMed (2021)
    — LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study
    View Source

  • PMC
    — Subcutaneous drug injection review: pharmacologic considerations
    View Source

  • NCBI Bookshelf
    — Best practices for injection (asepsis, preparation, and administration)
    View Source

  • ResearchGate (2021)
    — Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese mice
    View Source

  • PMC (2022)
    — Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice
    View Source

  • Scientific Reports / NMN.com
    — Role of NNMT inhibition in muscle strength: enhanced grip strength with exercise
    View Source

  • Swolverine
    — 5-Amino-1MQ mechanism, benefits, stacking and cycling guide
    View Source

  • CDC
    — Vaccine administration: subcutaneous route (angle/site; no aspiration)
    View Source

  • CDC (Subcut Injection PDF)
    — Technique diagram and site guidance for subcutaneous injections
    View Source

  • Journal of Medicinal Chemistry (ACS)
    — Bisubstrate inhibitors of NNMT with enhanced activity
    View Source

  • Pure Lab Peptides
    — 5-Amino-1MQ (10 mg) product page (quality and batch documentation)
    View Source